Daiichi Sankyo Escapes Antitrust MDL Over Generic Lipitor

Law360, Washington (November 19, 2013, 12:52 PM EST) -- A New Jersey federal judge on Monday released Daiichi Sankyo Inc. from multidistrict antitrust litigation challenging a patent infringement settlement between Pfizer Inc. and Ranbaxy Laboratories Inc. over Pfizer's cholesterol drug Lipitor, in which Daiichi Sankyo claimed it had no involvement.

In a short order, U.S. District Judge Peter G. Sheridan dismissed the case against Daiichi from the case, where several California pharmacies claimed it was involved in Ranbaxy Pharmaceuticals Inc.'s alleged anti-competitive agreement with Pfizer to delay generic Lipitor competition for longer than necessary....
To view the full article, register now.